title: Insufficient evaluation of adverse events is not a proof of safety.
authors.forename: L G
authors.initials: LG
authors.lastname: Hemkens
authors.forename: U
authors.initials: U
authors.lastname: Grouven
authors.forename: R
authors.initials: R
authors.lastname: Bender
authors.forename: P T
authors.initials: PT
authors.lastname: Sawicki
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic; D012449:Safety
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine